PCRX FY 2024 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$701M+3.9% YoY

Gross Profit

$531M75.7% margin

Operating Income

-$73M-10.5% margin

Net Income

-$100M-14.2% margin

EPS (Diluted)

$-2.15

Cash Flow

Operating Cash Flow

$189M

Free Cash Flow

$179M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$775M

Stockholders' Equity

$778M

Cash & Equivalents

$277M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$701M	$675M	+3.9%
Gross Profit	$531M	$490M	+8.2%
Operating Income	-$73M	$88M	-183.7%
Net Income	-$100M	$42M	-337.3%